A growing body of evidence suggests oncogenic roles for PTK6 in breast cancers, and targeting its kinase activity by small molecule inhibitors has been proposed as a potential therapy for the treatment of breast cancers [11, 19, 20]. This evidence concerns the gene PTK6 and breast cancer.